After validating the identity and immunoreactivity of each protein target, we next apply DropBlot to investigate a pilot cancer-protein panel composed of an epithelial marker (EpCAM), a mesenchymal marker (vimentin, VIM), and human epidermal growth receptor 2 (HER2) in a pilot group of breast cancer patient-derived cell samples. Here, VIM is linked to breast carcinoma.